As we move into the rest of 2022, it seems that biotech stocks could continue to be a viable play in the stock market. This can be attributed to the ongoing coronavirus concerns fueling the booming industry. Now, as the Omicron variant sweeps the globe, it shouldn’t come as a surprise as many investors continue to look out for the best biotech stocks to buy. Despite daily new cases seeming to be slowing down in the U.S, the persistent uncertainty has weighed on investors’ expectations regarding the overall market.
Also, with rising interest rates hampering tech stocks, the biotech segment does seem appealing these days, given its non-cyclical nature.
This post appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.